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Background: Malaria remains a major worldwide public health problem with ~207 million cases and ~627,000
deaths per year, mainly affecting children under five years of age in Africa. Recent efforts at elaborating a genetic
architecture of malaria have focused on severe malaria, leading to the identification of two new genes and
confirmation of previously known variants in HBB, ABO and G6PD, by exploring the whole human genome in
genome-wide association (GWA) studies. Molecular pathways controlling phenotypes representing effectiveness of
host immunity, notably parasitemia and IgG levels, are of particular interest given the current lack of an efficacious
vaccine and the need for new treatment options.
Results: We propose a global causal framework of malaria phenotypes implicating progression from the initial
infection with Plasmodium spp. to the development of the infection through liver and blood-stage multiplication
cycles (parasitemia as a quantitative trait), to clinical malaria attack, and finally to severe malaria. Genetic polymorphism
may control any of these stages, such that preceding stages act as mediators of subsequent stages. A biomarker of
humoral immunity, IgG levels, can also be integrated into the framework, potentially mediating the impact of
polymorphism by limiting parasitemia levels. Current knowledge of the genetic basis of parasitemia levels and
IgG levels is reviewed through key examples including the hemoglobinopathies, showing that the protective
effect of HBB variants on malaria clinical phenotypes may partially be mediated through parasitemia and
cytophilic IgG levels. Another example is the IgG receptor FcγRIIa, encoded by FCGR2A, such that H131
homozygotes displayed higher IgG2 levels and were protective against high parasitemia and onset of malaria symptoms
as shown in a causal diagram.
Conclusions: We thus underline the value of parasitemia and IgG levels as phenotypes in the understanding of the
human genetic architecture of malaria, and the need for applying GWA approaches to these phenotypes.
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Malaria remains a major worldwide public health prob-
lem in spite of numerous international control efforts
with ~207 million cases in 2012 and ~627,000 deaths
per year, mainly affecting children under five years of
age in Africa (http://www.who.int/en/). Malaria in humans
is caused by infection with the protozoan Plasmodium
spp., falciparum, vivax, ovale, malariae or knowlesi. Plas-
modium falciparum is responsible for the most severe
form of malaria. No efficacious malaria vaccine exists, and
current treatment options are threatened by the spread of* Correspondence: anavaj@pasteur.fr
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unless otherwise stated.drug resistant parasite strains. The malaria parasite has
a complex lifecycle, initiated when an infected female
Anopheles mosquito takes a bloodmeal, during which
sporozoites are injected into the bloodstream and then
invade liver cells. After asexual replication in the liver,
merozoites are released into the blood and further
asexual multiplication occurs in red blood cells. Mero-
zoites mature into trophozoites, and a small proportion
develop into female and male gametocytes, infectious
to the mosquito, thereby completing the cycle. In en-
demic regions, it is expected that most individuals will
become infected at some time, and a small fraction go
on to develop life-threatening severe malaria with com-
plications such as cerebral malaria, respiratory distress,
or anemia. Detectable parasitemia is used to diagnosehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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malaria (http://www.who.int/en/). The search for human
genetic factors that influence parasitemia levels and other
markers of anti-malarial host immunity could lead to
novel molecular strategies for vaccine and treatment de-
velopment, and malaria control. We therefore explore the
potential of quantitative measures of malaria infection, in-
cluding parasitemia and the biomarker of humoral host
immunity, IgG levels, in the search for human genetic fac-
tors impacting on malaria, in this review.
Review
Genome-wide association (GWA) studies of malaria
Recent interest in identifying host genetic factors impact-
ing on malaria has focused on severe malaria in African
children using the genomewide association (GWA) study
approach. Two signals near well-known malaria pro-
tective variants in HBB and ABO were detected in a meta-
analysis including 5,425 cases [1], while a previous GWA
study did not identify any variants exceeding the genome-
wide threshold until after the causal sickle cell trait mu-
tation itself (HbS) was genotyped, illustrating the
difficulties of covering genetic variability in African popu-
lations [2]. A third GWA study conducted in a population
from Ghana identified two novel susceptibility genes,
ATP2B4, encoding a red blood cell calcium pump, and
MARVELD3, implicated in vascular adherence of infected
red blood cells [3]. A reappraisal of GWA study data ac-
cording to specific severe malaria subtype revealed oppos-
ing effects for the main African mutation underlying
G6PDH deficiency: for severe anemia, a risk effect was
observed, and for cerebral malaria, a protective effect,
showing that phenotypic heterogeneity had previously
masked this association. Numerous other genes previously
validated under a candidate gene approach were missed
by these same GWA studies, suggesting presence of fur-
ther phenotypic heterogeneity. In addition to mutations
underlying the hemoglobinopathies, notably the sickle cell
trait and the thalessemias, genes previously identified for
severe malaria using the candidate gene approach in-
clude those involved in: cytoadherence of infected red
blood cells to the endothelium (CD36), antigen recogni-
tion (HLA-B), antibody response (IL4) and the proinflam-
matory response (NOS2A) (reviewed in [4]). The paucity
of novel findings for severe malaria in spite of large sample
sizes in past GWA studies suggests that phenotypic het-
erogeneity needs to be addressed, and that other malaria
phenotypes merit further exploration, including parasit-
emia and IgG levels.
The genetic basis for malaria infection phenotypes
Population-level observations, familial aggregation, and
complex segregation analyses have established the gen-
etic basis of parasitemia levels and IgG levels, providingthe groundwork for the identification of novel protective
or susceptibility variants. Parasitemia as a quantitative
trait is usually an aggregate measure per individual from
a longitudinal study (typically the mean or the maximum
across values), with each measure defined as a density
per uL of whole blood or as a percentage of red blood
cells positive for trophozoites. Studies have generally fo-
cused on P. falciparum parasitemia. Mean parasitemia
levels were found to differ between ethnicities based on
studies conducted in Burkina Faso, Mali and Nepal for
communities living in the same geographic area with
similar levels of exposure to P. falciparum (reviewed in
[4]). With respect to IgG levels, twin studies have re-
vealed higher concordance for monozygotic than dizy-
gotic twins for antibody response to specific parasite
antigens, typically vaccine candidates [4]. Sibling correl-
ation coefficients have been estimated at 0.16 to 0.24
and for IgG levels and at 0.13 to 0.39 for sub-type spe-
cific IgG levels [4]. Segregation analyses have led to a
conclusion of complex genetic control for both parasitemia
and IgG levels based on populations from Cameroon,
Burkina Faso, and Papua New Guinea [4].
Heritability provides a measure of the human genetic
contribution (proportion of variance) to a phenotype. Sev-
eral estimates have been made addressing parasitemia dur-
ing clinical malaria attacks and during an asymptomatic
infection. In two communities from Senegal, one holoen-
demic for malaria and another with seasonal transmission
(mesoendemic), a heritability of 0.22 was obtained for
mean parasitemia during clinical attacks in both commu-
nities. A significant heritability of 0.13 for maximum para-
sitemia was obtained for mesoendemic transmission only.
A maximum asymptomatic parasitemia heritability esti-
mate of 0.22 was obtained for both communities, and a
significant heritability of 0.33 for mean asymptomatic
parasitemia was obtained for the endemic community [5].
In a hypoendemic region of Thailand characterized by co-
infection with both P. falciparum and P. vivax malaria,
mean and maximum trophozoite densities during clinical
episodes displayed similar heritabilities to those obtained
in Senegal for both P. falciparum (0.16 and 0.16) and P.
vivax (0.13 and 0.15) [6]. In an exploration of risk factors
of potential human infectiousness to mosquitoes (carriage
of gametocyte stage parasites), there was significant herit-
ability of P. falciparum gametocyte prevalence (0.15 -
0.57) for asymptomatic infections, but not during clinical
attacks [7]. There is thus consistent evidence for human
genetics contributing to a significant proportion of the ob-
served variance in asexual and sexual parasite phenotypes
with differences according to endemicity, parasite species,
and whether the infection was symptomatic or not.
Genome-wide linkage studies have been performed on
various study populations leading to the identification of
loci controlling parasitemia. Chromosomal region 5q31-
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Th2 balance, was linked to parasitemia among families in
Cameroon [8] and in two independent study populations
from Burkino Faso (reviewed in [4]), and more specifically
to asymptomatic parasitemia in Burkina Faso [4] and
Senegal [5]. The analogous mouse model region has also
been identified for mouse malaria phenotypes [4]. The
MHC region was linked to mild malaria in several stu-
dies, with chromosome 6p21 linked to asymptomatic
parasitemia (reviewed in [4]). Other loci for the two re-
lated phenotypes, parasitemia (asymptomatic or during
a clinical attack) and mild malaria, have been identified
at 1p36, 2p25, 4q13-q21, 5p15-p13, 6p25.1, 6q15-q16,
9q34, 12q21-q22, 13q13, 10p15, 17p12, 19p13.12,
20p12 and 20q11 (reviewed in [4]).
Parasitemia as a quantitative endophenotype
Parasitemia can be considered to be the result of two
opposing forces in a tug-of-war, the pressure exerted by
the malarial parasite in its multiplicative red blood cell
stage, versus the pressure of anti-malarial immunity. The
higher the parasitemia, the greater the malarial force,
and the lower the force of anti-malarial immunity. For
the study of human genetics, it would be optimal to focus
on a measure of parasitemia that represents the globalFigure 1 Causal diagrams going from Plasmodium spp. infection to se
A. Two possible pathways going from infection to parasitemia, via IgG-med
multiple possible pathways for the impact of genetic polymorphism on IgG
Plasmodium falciparum as the infective species, and the influence of geneti
for H131 vs. heterozygotes & homozygotes for R131 (recessive model) actin
using DAGittyv.2.0 (http://www.dagitty.net/).effectiveness of anti-malarial host immunity, which would
assume factors contributing to malarial parasite pressure
to be homogeneous across the study population, including
parasite species and strain, and that all other parameters
impacting on parasitemia, such as the initial parasite dose,
are homogeneous or controlled for. Also, factors such as
nutritional status, which affect host immunity without
reflecting innate effectiveness should be constant in the
population. These assumptions are met in part in the lon-
gitudinal study design that is limited geographically with
contained vectorial transmission, and focused on a com-
munity with a similar lifestyle and socio-economic status
as in a longitudinal study following an endemic com-
munity in Senegal for 22 years [9]. Host immunity is
also known to vary with age and sex, which can be ad-
justed for. Under such homogeneous, controlled condi-
tions, causal diagrams can offer a heuristic framework
with which to evaluate potential causal pathways, high-
lighting genetic factors of interest (see Figure 1A) [10]. A
progression is implied, going from the initial infection
with Plasmodium spp. to the development of the infection
through liver and blood-stage multiplication cycles (para-
sitemia as a quantitative trait), to clinical malaria attack,
and to severe malaria. The initial infection stimulates
the immune system, elicits protective IgG antibodiesvere malaria through parasitemia and clinical attack.
iated acquired immunity or directly from infection to parasitemia, and
, parasitemia, clinical attack or severe malaria. B. An example specifying
c polyporphism at FcγRIIa distinguishing between FcγRIIa homozygotes
g on parasitemia via IgG2 levels. The causal diagrams were created
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aspect of anti-malarial host immunity. The arrows imply a
causal relationship but do not imply a particular direction
(increase or decrease). Arrows point from genetic poly-
morphism to all malaria phenotypes, indicating that all hy-
potheses are possible until tested, and thus the causal
framework can be thought of as summarizing the working
hypotheses which can then be reduced and refined as
study results are obtained. Parasitemia occurs early in the
causal pathway, prior to clinical symptoms and can be
considered a malaria endophenotype. Genetic association
studies evaluating specific polymorphisms can be tested
for association with any of the measurable phenotypes in
the causal progression, including parasitemia and IgG
levels. Previous parasitemia candidate gene studies will be
reviewed with examples considered in the context of this
causal framework for the complex scenarios involving me-
diation through IgG levels. The candidate gene studies of
parasitemia involve evaluation of the causal arrow from
genetic polymorphism to parasitemia.
The first genetic association studies with malaria pa-
rasitemia levels began with the observation of the co-
occurrence of geographic regions of high malaria preva-
lence and high prevalence of certain hemoglobinopathies
[11]. Hemoglobinopathies belong either to the category
of structurally variant forms of hemoglobin (such as
sickle cell trait) or the thalassaemias, resulting in re-
duced or absent production of molecules forming nor-
mal adult hemoglobin A. Allison first reported a major
role for the sickle cell mutation (HbS) in the β-globin
gene in the protection against P. falciparum parasitemia
as a binary trait in 1954 [12]. He also noted that subjects
with HbS displayed a lower proportion of moderate
parasitemia and none displayed severe parasitemia com-
pared to homozygous HbA individuals [12]. Genetic as-
sociation studies of the hemoglobinopathy variants with
mild malaria phenotypes have recently been compiled in
a systematic review and meta-analysis [13], where parasit-
emia was considered as a binary trait in a cross-sectional
design and compared to healthy controls. Neither HbS
nor the thalassemia variants were found to protect against
parasitemia. Studies evaluating parasitemia quantitatively
and longitudinally have found contrasting results for the
evidence of the impact of HbS heterozygotes on parasite
density, with some observations of lower levels compared
to HbA homozygotes [14], others displaying similar levels
[15] or even higher levels [16]. Given the contrasting re-
sults, in the context of the literature, it appears that the
casual arrow from HbS to parasitemia holds, such that in
part, parasitemia is a mediator of the association leading
to clinical malaria, and the arrows from polymorphism
directly to clinical attack and severe malaria also hold,
such that part of the association with clinical malaria phe-
notypes is independent of parasitemia (Figure 1A).Genetic association studies of parasitemia as a quantita-
tive trait have been conducted using a candidate gene ap-
proach, focused on immune signaling genes or to evaluate
whether parasitemia mediates previously discovered as-
sociations with clinical malaria. ABO blood group has
been shown to impact on clinical malaria risk with group
O in P. falciparum malaria-endemic regions displaying a
protective effect. Following from this observation, lowest
mean parasitemia was observed for group O compared to
A, B or AB groups consistently across studies (reviewed in
[17]). Genetic disorders of the red blood cell membrane,
including hereditary spherocytosis and southeast Asian
ovalocytosis, have been associated with resistance to mal-
aria infection. Hereditary spherocytosis has been associ-
ated with lower parasitemia [18], while ovalocytosis has
not revealed differential parasitemia levels (reviewed in
[19]). Several immune response genes have been associ-
ated with parasitemia levels including toll-like receptor
gene polymorphisms. IL4, IL12B, LTA, NCR3 have either
been linked to mild malaria or parasitemia, alleles in these
genes have been associated with these phenotypes
(reviewed in [20]). Promoter polymorphisms in TNF have
been associated with lower levels of parasitemia [21]. In a
family-based study from Burkina Faso, significant interac-
tions impacting on parasitemia levels were identified in-
volving HBB variant HbC and LTA + 80 or IL12B
polymorphisms [22]. In a linkage study conducted in a
Senegalese study population followed up by family-based
association tests within linked regions, a polymorphism in
ARHGAP26 was found to be associated with intensity of
plasmodial infection in the 5q33.1 region [23]. Interest-
ingly, a hypothesis-free approach led to the identification
of a compelling candidate gene: the protein encoded by
ARHGAP26 is implicated in regulation of Rho family sig-
nal transduction of endothelial receptors of P. falciparum
infected red blood cells [23]. Other pathways have also
been explored such as the heparan sulphate biosyn-
thesis pathway [24]. These studies were conducted using
a hypothesis-driven approach and provide a proof of
principle of the potential for parasitemia as a phenotype
to reveal genetic associations. Thus, for some of these
polymorphisms, parasitemia appears to be the mediator
of associations with clinical malaria phenotypes, while
for others the associations with clinical malaria pheno-
types are independent of parasitemia. Therefore, parasit-
emia may also enable the discovery of new associations
using hypothesis-generating GWA approaches.
The functional imperative and IgG levels
A key potential mediator of anti-malarial host immunity
is IgG: passive transfer of IgG, purified from sera of
semi-immune adults to non-immune patients resulted in
clearance of parasitemia [25]. The potential to clear pa-
rasitemia depends upon IgG subtype. Specifically,
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finity to Fc receptors on phagocytic cells, thereby acti-
vating effector mechanisms, while IgG2 and IgG4 bind
with lower affinity (reviewed in [25]). Numerous epi-
demiological studies have investigated IgG levels by
subtype, antigen specificity and level of antibody pro-
duction to determine the features most important in
determining clinical immunity with consideration for
seasonality [26]. Studies identifying IgG levels or
subtype-specific IgG levels as mediators of association
between genetic polymorphisms and malaria pheno-
types provide a clear framework for the functional hy-
pothesis connecting the polymorphism to malaria,
implicating IgG synthesis molecular pathways.
Several studies have investigated the role of IgG levels
as a mediator of HBB polymorphism on parasitemia
levels. For example, a study in a population in Burkina
Faso with a frequency of 0.14 of the C beta-globin allele
(hemoglobin C, HbC), and a low frequency of the S
allele, showed reduced maximum P. falciparum parasi-
temia levels among HbC subjects [27]. HbC was po-
sitively associated with anti-malarial IgG levels in the
same population, suggesting that HBB polymorphisms
alter anti-malarial IgG production [20]. HbS has also
been tested for association with IgG subclasses in Gabon
[28], and, adding another layer of specificity, another
study looked at IgG responses to the parasite’s major
cytoadherence ligand, P. falciparum erythrocyte mem-
brane protein 1 (PfEMP1). Complex causal hypotheses
(Figure 1A) can thus be constructed based on these re-
sults, with Plasmodium species specificity, IgG sub-type
and antigen specificity that would require validation in
subsequent studies, and complement the studies men-
tioned above focused on parasitemia only. Similar studies
investigating the role of IgG levels have been conducted
for other polymorphisms associated with parasitemia
levels, for example the protective effect of TNF pro-
moter polymorphisms may be partly due to their effect on
IgG subclass production [20], and an association of anti-
malarial IgG levels with IL4-590 has been reported [29].
Protective immunity in malaria is at least in part trans-
ferred through antibodies, and the probable modes are
through inhibition of merozoite invasion of erythrocytes
and/or a role for Ab/complement mediated phagocytosis
via Fc-receptors (FcRs), although which of the large fam-
ily of human FcRs are optimally involved remains un-
clear [30]. Important examples include receptors for IgG
(FcγRI, FcγRII, FcγRIII, FcRn), IgE (FcɛRI), IgA (FcαRI,
Fcα/μR, pIgR) and IgM (Fcα/μR) [30]. Several associ-
ation studies have focused on FCGR2A that encodes the
human IgG receptor FcγRIIa [30]. Although IgG2 gener-
ally binds Fc receptors with low affinity, IgG2 levels were
associated with a protective effect against malaria among
individuals homozygous for the FCGR2A H131 variant,which influences binding of IgG2 on neutrophils [31]. A
significant association of the FcγRIIa H131 allele with
IgG2 levels, based on a recessive model, was reported in
a family based study [20] and in independent population
based studies [32,33]. Thus, IgG2 appears to be a me-
diator of the effect of H131 homozygotes leading to a
protective effect on malaria clinical disease [34]. The spe-
cific causal pathway for this association is represented in
Figure 1B. The polymorphism FcγRIIa R131H acts on
parasitemia via IgG2 levels as a mediator (Figure 1B) from
genetic polymorphism to IgG2.
Carriers of Glucose-6-phosphate dehydrogenase defi-
ciency (G6PD deficiency) alleles are partially protected
against malaria. In a study of children in an area with
seasonal malaria transmission in Senegal, G6PD A- car-
riers had a lower increase of IgG3 levels to merozoite
surface antigens during the transmission season than the
non-carriers, which is consistent with carriers having a
lower burden of merozoites, and indicative that protective
immunity is likely to occur through other mechanisms
than through humoral immunity. Such mechanisms could
be cell-mediated immunity and/or physiological conse-
quences of the blood disorder could explain clinical
protection [35]. In a study specifically investigating the
impact of the mutation G6PD-Mahidol (487A) on a
population infected with both P. falciparum and P. vivax,
the variant form was associated with protection from high
P. vivax parasite density, but not high P. falciparum para-
site density in humans, indicating Plasmodium spp. spe-
cificity for the protective effect [36]. Along with G6PD
deficiency leading to protective or susceptibility effects de-
pending on specific severe malaria phenotype as men-
tioned above, collectively, these studies demonstrate the
causal relationship from G6PD deficiency to IgG subtype
to parasite species specificity, to parasitemia levels and
clinical malaria specificity. Population level longitudinal
studies focused on quantitative traits, such as parasitemia
levels and IgG subtype levels, and specification of the
severe malaria phenotype, enabled the identification of
genetic associations that also provide insight into the
functional relationship between the polymorphisms at
this gene and disease.
Conclusions
Although to date, the main phenotypic focus of studies
on the human genetics of malaria have been on severe
malaria, we show here, through key examples, that mal-
aria infection, viewed as a collection of related quantita-
tive traits, particularly parasitemia and sub-type specific
IgG levels, has high potential to increase understanding
of the genetic architecture of malaria. Studies focusing
on these phenotypes act as a bridge between genetic as-
sociation studies and functional studies, and enable the
elaboration and verification of highly specific hypotheses
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phenotypes and genetic polymorphism genotypes may
be linked causally. A recent focus on severe malaria only
has been demonstrated to be short-sighted given the
paucity of new findings to come from GWA studies.
Looking to future studies, there is clearly potential for
further exploiting the information available in longitu-
dinal studies that have measured parasitemia at regular
intervals by considering the rate of change in parasit-
emia levels as well as absolute levels. This is especially
true for malaria, where the acquisition of clinical immu-
nity develops only after repeated clinical episodes and
completely sterilizing immunity is never achieved. A lon-
gitudinal GWA study could thus reveal novel genetic vari-
ants controlling parasitemia levels. Regarding the study of
IgG levels, most studies either evaluate total levels by sub-
type or focus on response to a single antigen at a time.
Multivariate statistical methods considering IgG levels
against a panel of relevant antigens IgG simultaneously,
adapted to GWA studies are needed to optimally capture
relevant response. Furthermore, genomics approaches
could also be applied to all Plasmodium spp. to more
fully account for pathogen variability.
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